RxDoctor Payments Data

Timothy Wirth, MD

Internal Medicine · Reading, PANPI 1396741765

Payments from drug & device makers

$693in general payments, 2019–2025

Across 45 payments — averaging $15.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$94
  • Novo Nordisk$82
  • AstraZeneca$81
  • GSK$66
  • Boehringer Ingelheim$64
  • Lilly USA, LLC$40
  • plus $266 from 11 others

What the payments were for

  • Food & beverage$693100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$693 in reported general payments places this provider in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$178,912
Medicare patients
516
Services billed
1,801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban224$252,399
JardianceEmpagliflozin64$90,528
FarxigaDapagliflozin Propanediol48$67,312
XareltoRivaroxaban54$62,142
JanuviaSitagliptin Phosphate46$42,469
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$33,064
TrulicityDulaglutide20$27,033
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog55$26,645
Breo ElliptaFluticasone/Vilanterol42$25,479
OzempicSemaglutide22$23,238
MyrbetriqMirabegron28$19,381
EntrestoSacubitril/Valsartan12$13,760
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$12,043
Atorvastatin Calcium1,137$11,440
Lantus SolostarInsulin Glargine,hum.Rec.Anlog84$10,838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$33$255,258249 claims
Boehringer IngelheimJardiance$64$90,52864 claims
AstraZenecaFarxiga$81$67,31248 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$66$62,83696 claims
Johnson & JohnsonXarelto$38$62,14254 claims
MerckJanuvia$11$42,46946 claims
Lilly USA, LLCTrulicity$40$27,03320 claims
Novo NordiskOzempic$82$23,23822 claims
Astellas Pharma US IncMyrbetriq$16$19,38128 claims
NovartisEntresto$25$13,76012 claims
AbbVieSynthroid$37$4,852104 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Reading

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →